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BACKGROUND. Substantial variation in adjuvant breast cancer chemotherapy dos-
ing in obese women suggests that there is uncertainty about optimal practices.
The purpose of this study was to investigate variations in dose determinations in
clinical trial protocols and publications over the last 3 decades as potential
sources of this uncertainty.
METHODS. The National Cancer Institute database was used to identify protocols
of breast cancer adjuvant chemotherapy conducted by cooperative groups
between 1970–2000, and these protocols were then obtained directly from the co-
operative groups. Dose determinations were categorized in each protocol and in
published reports from each clinical trial. Fisher exact tests were used to com-
pare the proportions of protocols that used full weight-based doses over time.
RESULTS. Protocol-specified chemotherapy dosing was obtained for all of 44 eligi-
ble trials. A significant increase was identified in the use of full weight-based
doses in the later time period compared with the earlier (P 5 .004; 2-sided Fisher
exact test). A notable exception was 1 cooperative group that continues to require
dose limitations for doxorubicin and cyclophosphamide in patients with a body
surface area of more than 2.0 m2. Regardless of publication date, published
reports of clinical trials rarely provide information on use of full or limited
weight-based doses.
CONCLUSIONS. Variations in dose determinations among clinical trial protocols
and lack of information on use of full weight-based doses in most publications
are 2 likely sources of variation in chemotherapy dosing in obese women. Devel-
oping consensus and disseminating information on optimal chemotherapy dos-
ing will likely reduce such variation and may improve survival among obese
patients with breast cancer. Cancer 2008;112:2159–65.  2008 American Cancer
Society.
KEYWORDS: breast cancer, obesity, clinical trials, practice variations, practice
guidelines.
C hemotherapy doses in the adjuvant treatment of breast cancerare generally normalized to body by size using the patient’s
body surface area (BSA). The BSA is, in turn, calculated by using
height and weight according to one of several methods.1 Although
the majority of overweight and obese women are treated with full
weight-based chemotherapy doses, the practice of administering
reduced doses (compared with those doses that would be expected
if actual weight were used to calculate chemotherapy) to heavy
women is common.2–5 For example, in a national study of patients
treated in 901 practices with adjuvant chemotherapy for breast can-
cer between 2002 and 2005, 13.8% of overweight patients, 17.7% of
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obese patients, and 26.6% of severely obese women
received initial dose reductions of greater than 15%
when compared with doses that would have been
given had full weight-based dosing been used.
Reduced doses were not explained by age, comorbid-
ity, or other clinical factors.6 The use of reduced
doses varies according to treating physician2 and
even according to geographic region.6 Such practice
variation suggests that there is uncertainty about the
optimal dosing of chemotherapy, including perhaps
the safety and necessity of using actual body weight
when calculating chemotherapy doses. Uncertainty
clearly persists despite compelling evidence that full
weight-based doses are not only safe but also neces-
sary if the full benefit of chemotherapy is to be
achieved.7–9
The purpose of the current study was to answer
the following questions: 1) How have cooperative
groups specified that chemotherapy doses be deter-
mined in obese patients? That is, do protocols spe-
cify the use of full weight-based doses or a dosing
limit? 2) Is there variation among cooperative groups
in how chemotherapy doses are determined? 3) How
much information is available on chemotherapy dose
determinations in published articles from coopera-
tive group trials?
The premise of this study is that clinical trial
protocols provide a standard of care for prescribing
physicians with respect to such issues as dose deter-
minations in studies of nonmyeloablative chemo-
therapy. A second premise is that physicians use
published medical literature to inform their chemo-
therapy-prescribing decisions and that lack of infor-
mation on dosing contributes to uncertainty about
best chemotherapy dosing practices in the treatment
of obese women.
MATERIALS AND METHODS
Dose determinations in cooperative group clinical
trials are not compiled in a central source, and publi-
cations rarely provide information on dosing limits
(see below). Primary data collection thus involved
the retrieval of study protocols from cooperative
groups in the United States and in Europe. We used
the Physician Data Query (PDQ) of the National Can-
cer Institute (NCI) to identify all registered and com-
pleted cooperative group, nonmyeloablative, breast
cancer, adjuvant chemotherapy clinical trials. The
search, which was conducted in August 2005 and
repeated in April 2007, was limited to closed proto-
cols that enrolled female patients with stage I, II, or
III breast cancer and that used chemotherapy. We
did not limit by geographic location or trial activa-
tion date. Each trial in the generated set of trials was
individually examined and required to meet the fol-
lowing criteria. We included only adjuvant, nonmye-
loablative, chemotherapy trials that were authored by
1 or more cooperative groups. Myeloablative regi-
mens that required stem-cell support or bone-mar-
row support were excluded because the doses of
chemotherapy used in myeloablative regimens are
generally several-fold higher than those used in
standard adjuvant regimens, and there is little infor-
mation on safety of full weight-based doses in this
setting. The only remaining inclusion criterion for
each trial was the publication of an article or articles
that reported patient survival by using data from no
more than 2 clinical trials. Written protocols were
requested from each cooperative group.
Dosing instructions were categorized into 1 of 3
categories: 1) full weight-based dosing, 2) dose
adjustment or maximum limit in heavy patients
(ideal or corrected body weight used to calculate BSA
or a maximum BSA ‘‘cap’’), or 3) no specific instruc-
tions.
We searched PubMed, Ovid, the NCI database,
the cooperative group websites, and the Dana Farber
Cancer Institute database to identify for each trial a
published article that focused on outcomes. In cases
where more than 1 article reported on outcomes, 1
article was selected at random. For each article, dose
determinations in obese patients were categorized
into 1 of the 3 categories described above.
Fisher exact test was used to compare the pro-
portion of trials that specified use of full weight-
based dosing (no dose limits) during the study time
period and the proportion of published studies that
provided information on the use of full doses versus
limited doses.
Permission was obtained from either the cooper-
ative group chairperson or disease-site chairperson
of the cooperative group to allow us to publish infor-




Search criteria generated 44 eligible clinical trials
from the NCI database spanning the years 1970
through 2000. Dosing instructions were successfully
obtained for all. The included protocols are listed in
Table 1.
Eleven (25%) of the protocols used actual body
weight in dose determinations. Nineteen (43%) speci-
fied some form of dose limits, whether through use
of ideal body weight, the lesser of actual or ideal
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body weight, adjusted ideal body weight, or a BSA
limit of 2.0 m2. Dose determinations changed over
time (Fig. 1) and were more likely to be specified in
later protocols. Of the 22 protocols initiated through
December 1984, 21 (95%) either did not directly
address dose determinations in heavy patients
(n 5 9) or specified dose reduction (n 5 12) in heavy
patients. One trial specified use of actual body
weight in dose determinations. Of the 22 protocols
initiated after 1984, 10 (45%) specified full weight-
based dosing, 7 (32%) specified dose limits, and 5
(23%) provided no specific information on chemo-
therapy dosing in heavy patients. The difference in
the use of full weight-based doses in the 2 time peri-
ods was significant (P 5 .004; 2-sided Fisher exact
test). All protocols that required dose limits were
authored by 1 cooperative group and specified dose
limits only for cyclophosphamide and doxorubicin;
no dose limitations were specified for taxanes. The 4
remaining US cooperative groups required full
weight-based doses in protocols initiated after 1984.
Clinical Trial Publications
Information on chemotherapy dose determinations
in published clinical trial reports corresponding to
cooperative group protocols is shown in Figure 2. Of
the 43 published articles (1 article reported on find-
ings from 2 trials; see Table 2), information on dose
determination in heavy patients was included in only
10 (23%). Dosing information was provided in 8
(42%) of the 19 publications from studies that speci-
fied dose limits compared with only 2 (18%) of the
11 that used actual weight-based doses, but this dif-
ference was not statistically significant (P 5 .25; 2-
sided Fisher exact test).
DISCUSSION
Early cooperative group protocols included in the
Physician Data Query of the National Cancer Insti-
tute used dose limits or did not address dosing prac-
tices in obese patients. Over the last 2 decades, all
but 1 of the United States cooperative groups and 1
of the 2 European cooperative groups have specified
use of actual body weight with no dose limitations in
trial participants. Information on dosing practices is
generally lacking in published reports of these clini-
cal trials.
A substantial body of research supports the use
of full weight-based doses in heavy patients who are
receiving adjuvant chemotherapy for breast cancer.7–14
There is no evidence that use of actual body weight
to determine chemotherapy doses is associated with
greater myeloid or nonmyeloid toxicity.2,7–12 More-
over, receipt of full weight-based doses appears to be
required for patients, particularly for those with
estrogen receptor-negative tumors, to achieve the full
benefit of chemotherapy.7,9 For example, in 1 clinical
trial of adjuvant chemotherapy with cyclophospha-
mide, doxorubicin, and 5-fluorouracil, obese patients
who had a 5% or greater reduction in chemotherapy
doses below those expected if actual body weight
were used had inferior failure-free survival.7 Likewise,
TABLE 1
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in a pooled analysis of 4 adjuvant chemotherapy
trials, obese patients with hormone receptor-negative
breast cancer who received less than 85% of full
weight-based doses had inferior disease-free and
overall survival.9 On the basis of available evidence,
the Southwestern Oncology Group (SWOG) generated
a written policy in 2001 (Siu-Fun Wong, PhD, perso-
nal communication) that actual body weight should
always be used in calculating treatment doses in
patients who are participating in clinical trials. The
Cancer and Leukemia Group B (CALGB) considers
failure to use actual body weight in the calculation
of drug doses to be a major protocol deviation.
Despite evidence against dose limits in heavy
patients who are receiving adjuvant breast cancer
chemotherapy, many obese and overweight patients
receive reduced chemotherapy doses as described
above.2–5 The present-day practice of limiting adju-
vant chemotherapy doses in heavy patients and the
finding that use of reduced chemotherapy doses var-
ies according to provider suggests that there is persis-
tent uncertainty about best practices for this patient
population. The finding that the protocols of 1 of the
largest cooperative groups specify dose limits of cy-
clophosphamide and doxorubicin suggests that
uncertainty may also exist among clinical trialists.
FIGURE 1. These are dose instructions for cooperative group clinical trials. Each shape represents 1 of 44 protocols, 19702001. The timeline beneath
represents 5-year intervals. The included protocols are listed in Table 1. Legend: l, full weight-based doses; *, dose reduction (includes dose adjustment by
use of ideal body weight, less or ideal or actual body weight, adjusted ideal body weight, or ‘‘capping’’ at 2 m2); X, not specified in the protocol. CALGB
indicates Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; FRE-FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer;
IBCSG, International Breast Cancer Study Group; NCCTG, North Central Cancer Treat Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; SWOG,
Southwestern Oncology Group.
FIGURE 2. Dose determination instructions for each of 43 publications are shown. The timeline beneath represents 5-year intervals. Dates indicate the date
the trial began to enroll patients. Publication dates are available in Table 2. Legend: l, full weight-based doses; *, dose reduction (includes dose adjustment
by use of ideal body weight, less or ideal or actual body weight, adjusted ideal body weight, or ‘‘capping’’ at 2 m2); X, not specified. CALGB indicates Cancer
and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; FRE-FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer; IBCSG, Interna-
tional Breast Cancer Study Group; NCCTG, North Central Cancer Treat Group; NSABP, National Surgical Adjuvant Breast and Bowel Project; SWOG, Southwestern
Oncology Group.
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TABLE 2
Breast Cancer Adjuvant Chemotherapy Publications
Cancer and Leukemia Group B (CALGB)
Tormey DC, Weinberg VE, Holland JF, et al. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast
cancer. J Clin Oncol. 1983;1:138–145. (CALGB 7581)
Perloff M, Lesnick GJ, Korzun A, et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J
Clin Oncol. 1988;6:261–269. (CALGB 7784)
Budman DR, Korzun AH, Aisner J, et al. A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443.
Cancer Invest. 1990;8:571–575. (CALGB 8443)
Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253–1259.
(CALGB 8541)
Perloff M, Norton L, Korzun AH, et al. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer
and Leukemia Group B study. J Clin Oncol. 1996;14:1589–1598. (CALGB 8082)
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as
postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol.
2003;21:1431–1439. (CALGB 9741)
Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy
regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983. (CALGB 9344)
Eastern Cooperative Oncology Group (ECOG)
Taylor SG, Kalish LA, Olson JE, et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three year
results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:144–154. (ECOG 6177)
Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989;320:485–490.
(ECOG 1180)
Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone. (CMFP) or CMFP plus
tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer. 1990;65:200–206. (ECOG 5177)
Falkson HC, Gray R, Wolberg WH, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal
women with breast cancer: an Eastern Cooperative Oncology Group phase III study. J Clin Oncol. 1990;8:599–607. (ECOG 4181)
Tormey DC, Gray R, Abeloff MD, et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative
Oncology Group trial. J Clin Oncol. 1992;10:1848–1856. (ECOG 5181)
Olson JE, Neuberg D, Pandya KJ, et al. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern
Cooperative Oncology Group. Cancer. 1997;79:1138–1149. (ECOG 3181)
Fetting JH, Gray R, Fairclough DL, et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive,
receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998;16:2382–2391. (ECOG 3189)
Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast
cancer: results from INT 0101. (E5188). J Clin Oncol. 2005;23:5973–5982. (ECOG 5188)
Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01
Trial. J Clin Oncol. 2006;24:5664–5671. (FRE-FNCLCC-PACS-01)
Kerbrat P, Roche H, Bonneterre J, et al. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. Br J Cancer.
2007;96:1633–1638. (FRE-FNCLCC-GFEA-09)
International Breast Cancer Study Group (IBCSG)
Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol.
1996;14:1885–1894. (IBCSG VI)
Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. International Breast Cancer Study Group. J
Clin Oncol. 1997;15:1385–1394. (IBCSG VII)
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002;94:1054–1065.
(IBCSG IX)
Castiglione-Gertsch M, O’Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast
cancer: a randomized trial. J Natl Cancer Inst. 2003;95:1833–1846. (IBSCG VIII)
North Central Cancer Treatment Group (NCCTG)
Perez EA, Suman VJ, Davidson NE, et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central
Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004;22:3700–3704. (NCCTG-N9831)
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Fisher B, Carbone P, Economou SG, et al. 1-Phenylalanine mustard. (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med.
1975;292:117–122. (NSABP B-05)
Fisher B, Glass A, Redmond C, et al. L-phenylalanine mustard. (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with
those utilizing L-PAM plus 5-fluorouracil. (5-FU). Cancer. 1977;39:2883–2903. (NSABP B-07)
Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6. (NSABP B-09)
(continued)
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Dose determinations specified within clinical
trial protocols may serve as a form of guideline for
chemotherapy dosing in heavy patients, even in
patients being treated ‘‘off protocol.’’ The lack of in-
formation on chemotherapy dosing in most of the
corresponding published articles further indicates
that physicians may not have sufficient information
on standard practices in the dosing of obese patients.
Without specific information to the contrary, a physi-
cian may elect to fall back on older practices of lim-
iting doses in the heavy patient.
Our study is restricted to published cooperative
group trials registered in the Physician Data Query.
The findings of this survey thus cannot be general-
ized to all published clinical trials of adjuvant breast
cancer chemotherapy. Nonetheless, cooperative group
trials are highly influential, and their publications are
widely cited.
We contend that present-day variations in chem-
otherapy dosing in heavy patients represent unwar-
ranted variation.15 Developing and disseminating
standards for dose determinations in heavy patients
is critical to decreasing variation in dosing practices
and may improve outcomes among obese women.
As the prevalence of obesity and severe obesity
increases,16 we suggest that cooperative groups come
to consensus on dose determinations in obese
patients on the basis of existing evidence and further
suggest that guideline-development groups and bio-
medical journals provide specific information on the
TABLE 2
(continued)
Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast
cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989;320:473–478. (NSABP B-13)
Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel
Project experience. J Clin Oncol. 1989;7:572–582. (NSABP B-11, B-12)
Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer
patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990;8:
1005–1018. (NSABP B-16)
Fisher B, Brown A, Wolmark N, et al. Evaluation of the worth of corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer.
Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer. 1990;66:220–227. (NSABP B-10)
Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of
cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant
Breast and Bowel Project B-15. J Clin Oncol. 1990;8:1483–1496. (NSABP B-15)
Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative
tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project. (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate
and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996;14:1982–1992. (NSABP B-19)
Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of
primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997;15:1858–1869. (NSABP B-22)
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical
Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483–2493. (NSABP B-18)
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89:1673–1682.
(NSABP B-20)
Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical
Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19:931–942. (NSABP B-23)
Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide:
preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–4174. (NSABP B-27)
Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP
B-28. J Clin Oncol. 2005;23:3686–3696. (NSABP B-28)
Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or
without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–
7819. (NSABP B-31)
Southwest Oncology Group (SWOG)
Glucksberg H, Rivkin SE, Rasmussen S, et al. Combination chemotherapy. (CMFVP) versus L-phenylalanine mustard. (L-PAM) for operable breast cancer with positive axillary
nodes: a Southwest Oncology Group Study. Cancer. 1982;50:423–434. (SWOG 7436)
Rivkin SE, Green S, Metch B, et al. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest
Oncology Group study. J Clin Oncol. 1993;11:1710–1716. (SWOG 7827)
Budd GT, Green S, O’Bryan RM, et al. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. J Clin
Oncol. 1995;13:831–839. (SWOG 8313)
Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005;23:24–29.
(SWOG 8897)
Linden HM, Haskell CM, Green SJ, et al. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis
from INT-0137. (S9313). J Clin Oncol. 2007;25:656–661. (SWOG 9313)
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standard of care for dosing obese patients who are
receiving adjuvant breast cancer chemotherapy.17
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